Alkermes (ALKS) Total Current Liabilities (2011 - 2026)
Alkermes' (ALKS) quarterly Total Current Liabilities came in at $662.1 million in Q2 2026, up 30.86% year-over-year from $506.0 million in Q2 2025, and up 10.44% quarter-over-quarter from $599.5 million in Q1 2026.
Analysis
Alkermes (ALKS) Total Current Liabilities (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Total Current Liabilities for 16 consecutive years, with $662.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Current Liabilities rose 30.86% year-over-year to $662.1 million in Q2 2026; TTM through Jun 2026 was $662.1 million, a 30.86% increase from a year earlier, with the FY2025 full-year figure at $543.4 million, up 16.82% from the prior year.
- Total Current Liabilities was $662.1 million for Q2 2026 at Alkermes, up from $599.5 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $662.1 million in Q2 2026 and troughed at $438.5 million in Q2 2022.
- A 5-year average of $499.7 million and a median of $490.0 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities decreased 10.58% in 2024 and jumped 35.1% in 2026, its largest moves.
- Over 5 years, Total Current Liabilities stood at $497.7 million in 2022, then rose by 4.52% to $520.2 million in 2023, then retreated by 10.58% to $465.2 million in 2024, then increased by 16.82% to $543.4 million in 2025, then grew by 21.83% to $662.1 million in 2026.
- The last three Total Current Liabilities figures came in at $662.1 million (Q2 2026), $599.5 million (Q1 2026), and $543.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.93 Bn | 625.17 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 443.06 Bn | 436.49 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 365.76 Bn | 358.62 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 266.47 Bn | 258.78 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 6 | Sanofi | 52.36 Bn | 44.98 Bn | 10.79 Bn | 37.11 Bn |
| 7 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - | 354.06 Mn |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | 1.31 Bn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn | 607.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 662.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 662.09 Mn |
| Mar 31, 2026 | 599.50 Mn |
| Dec 31, 2025 | 543.44 Mn |
| Sep 30, 2025 | 474.36 Mn |
| Jun 30, 2025 | 505.96 Mn |
| Mar 31, 2025 | 443.73 Mn |
| Dec 31, 2024 | 465.20 Mn |
| Sep 30, 2024 | 453.71 Mn |
| Jun 30, 2024 | 515.55 Mn |
| Mar 31, 2024 | 458.98 Mn |
| Dec 31, 2023 | 520.22 Mn |
| Sep 30, 2023 | 503.11 Mn |
| Jun 30, 2023 | 487.19 Mn |
| Mar 31, 2023 | 492.91 Mn |
| Dec 31, 2022 | 497.74 Mn |
| Sep 30, 2022 | 469.56 Mn |
| Jun 30, 2022 | 438.52 Mn |
| Mar 31, 2022 | 462.36 Mn |
| Dec 31, 2021 | 471.29 Mn |
| Sep 30, 2021 | 452.98 Mn |